NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis $20.31 +0.24 (+1.20%) Closing price 04:00 PM EasternExtended Trading$20.32 +0.01 (+0.02%) As of 06:18 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Forte Biosciences Stock (NASDAQ:FBRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Forte Biosciences alerts:Sign Up Key Stats Today's Range$19.80▼$20.9150-Day Range$20.07▼$35.0952-Week Range$7.00▼$35.80Volume133,695 shsAverage Volume230,280 shsMarket Capitalization$282.11 millionP/E RatioN/ADividend YieldN/APrice Target$67.00Consensus RatingModerate Buy Company Overview Forte Biosciences, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments to restore skin health by targeting the underlying biology of the skin barrier and microbiome. Headquartered in San Diego, California, Forte leverages proprietary platforms to discover and advance topical live biotherapeutic products and skin barrier therapies aimed at addressing serious dermatological conditions. The company’s lead product candidate, FB-401, is a topical live biotherapeutic formulation designed to rebalance the skin microbiome in patients with atopic dermatitis. FB-401 has shown promise in early studies for reducing inflammation and improving barrier function, and is currently being evaluated in Phase 2 clinical trials. In addition to atopic dermatitis, Forte is exploring pipeline opportunities in rare genetic skin conditions such as epidermolysis bullosa, where reinforcing the skin’s protective barrier is a critical unmet need. Forte Biosciences conducts clinical research across North America and Europe, collaborating with academic institutions and patient advocacy groups to accelerate development timelines. The company’s management team comprises professionals with extensive experience in biotechnology R&D, regulatory affairs, and commercial strategy, positioning Forte to translate scientific discoveries into potential therapeutic options for patients with chronic and rare skin disorders.AI Generated. May Contain Errors. Read More Forte Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreFBRX MarketRank™: Forte Biosciences scored higher than 46% of companies evaluated by MarketBeat, and ranked 568th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingForte Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialForte Biosciences has a consensus price target of $67.00, representing about 229.9% upside from its current price of $20.31.Amount of Analyst CoverageForte Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Forte Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Forte Biosciences are expected to grow in the coming year, from ($4.21) to ($4.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Forte Biosciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Forte Biosciences is -4.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioForte Biosciences has a P/B Ratio of 6.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Forte Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.81% of the float of Forte Biosciences has been sold short.Short Interest Ratio / Days to CoverForte Biosciences has a short interest ratio ("days to cover") of 4.43.Change versus previous monthShort interest in Forte Biosciences has recently increased by 22.91%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldForte Biosciences does not currently pay a dividend.Dividend GrowthForte Biosciences does not have a long track record of dividend growth. News and Social Media3.7 / 5News Sentiment0.86 News SentimentForte Biosciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Forte Biosciences this week, compared to 2 articles on an average week.MarketBeat Follows1 people have added Forte Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Forte Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders4.40% of the stock of Forte Biosciences is held by insiders.Percentage Held by Institutions77.63% of the stock of Forte Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Forte Biosciences' insider trading history. Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FBRX Stock News HeadlinesForte Biosciences (NASDAQ:FBRX) Upgraded at Wall Street ZenMay 18 at 1:09 AM | americanbankingnews.comForte Biosciences (FBRX) price target increased by 19.72% to 65.02May 15, 2026 | msn.comRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.May 20 at 1:00 AM | Porter & Company (Ad)Forte Biosciences (FBRX) to Release Quarterly Earnings on ThursdayMay 14, 2026 | americanbankingnews.comForte Biosciences (NASDAQ:FBRX) Lowered to "Strong Sell" Rating by Wall Street ZenMay 10, 2026 | americanbankingnews.comForte Biosciences prices 5.71M shares at $26.27 in $150M capital raiseApril 10, 2026 | msn.comForte Biosciences: 2026 Is Major Inflection Point For FB102April 10, 2026 | seekingalpha.comForte Biosciences: Stunning Bull Run Could Continue Thanks To Near-Term Data ReadoutsApril 10, 2026 | seekingalpha.comSee More Headlines FBRX Stock Analysis - Frequently Asked Questions How have FBRX shares performed this year? Forte Biosciences' stock was trading at $27.27 at the beginning of 2026. Since then, FBRX stock has decreased by 25.5% and is now trading at $20.31. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) released its quarterly earnings results on Monday, May, 11th. The company reported ($1.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.16) by $0.08. When did Forte Biosciences IPO? Forte Biosciences (FBRX) raised $94 million in an IPO on Thursday, April 13th 2017. The company issued 8,500,000 shares at $10.00-$12.00 per share. Who are Forte Biosciences' major shareholders? Forte Biosciences' top institutional investors include Janus Henderson Group PLC (8.55%), Candriam S.C.A. (0.61%), Stempoint Capital LP (0.42%) and Bank of America Corp DE (0.16%). Insiders that own company stock include Paul A Wagner and Antony A Riley. View institutional ownership trends. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Forte Biosciences investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), PayPal (PYPL), Qualcomm (QCOM), Avino Silver & Gold Mines (ASM), Meta Platforms (META) and Zoom Communications (ZM). Company Calendar Last Earnings5/11/2026Today5/20/2026Next Earnings (Estimated)5/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 FBRX's financial health is in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:FBRX CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees5Year Founded2001Price Target and Rating Average Price Target for Forte Biosciences$67.00 High Price Target$75.00 Low Price Target$61.00 Potential Upside/Downside+229.9%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($4.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$69.38 million Net MarginsN/A Pretax MarginN/A Return on Equity-106.17% Return on Assets-85.50% Debt Debt-to-Equity RatioN/A Current Ratio2.75 Quick Ratio2.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.03 per share Price / Book6.70Miscellaneous Outstanding Shares13,890,000Free Float13,275,000Market Cap$282.11 million OptionableOptionable Beta3.01 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:FBRX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredTrump Is Eyeing the Biggest Monetary Shift Since NixonOn August 15, 1971, Nixon ended the Bretton Woods agreement and untethered the dollar from gold. Since that ni...Americas Gold Company | SponsoredMusk's acquisition pattern points to ONE stockMusk needed solar - he acquired SolarCity. Needed data - he bought Twitter. The pattern is clear: when a suppl...Behind the Markets | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Forte Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
